M. A. Al Malki

发表

Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014.

M. V. D. van den Brink, S. Mineishi, D. Blaise, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant.

G. Marcucci, I. Aldoss, S. Forman, 2021, Blood advances.

Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.

D. Weisenburger, G. Marcucci, I. Aldoss, 2019, Clinical lymphoma, myeloma & leukemia.

Targeting miR‐126 disrupts maintenance of myelodysplastic syndrome stem and progenitor cells

F. Pichiorri, G. Marcucci, Dandan Zhao, 2021, Clinical and translational medicine.

PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.

S. Montoto, D. Blaise, P. Dreger, 2019, Blood advances.

The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation

S. Solomon, D. Blaise, A. Nagler, 2019, Bone Marrow Transplantation.

Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myeloid leukemia.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Identification of the Novel HLA-A*24:518N Null Allele and Evaluation of its Cell Surface Expression on Lymphocytes.

Jean F. Garcia-Gomez, K. Gendzekhadze, M. A. Al Malki, 2022, Transplantation.

The mythological chimera and new era of relapse prediction post-transplant.

S. Ciurea, S. Sana, M. A. Al Malki, 2022, Blood reviews.

Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016.

P. Hari, Richard J. Jones, Jeffrey S. Miller, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.

Lixin Yang, G. Marcucci, I. Aldoss, 2019, Blood advances.

Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity

I. Aldoss, J. Zaia, S. Forman, 2022, Blood Advances.

Total marrow irradiation (TMI): Addressing an unmet need in hematopoietic cell transplantation - a single institution experience review

An Liu, T. Schultheiss, J. Wong, 2022, Frontiers in Oncology.

Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.

A. Nademanee, L. Kwak, I. Aldoss, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

G. Marcucci, I. Aldoss, S. Forman, 2018, Haematologica.

Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.

G. Marcucci, I. Aldoss, S. Forman, 2019, Blood advances.

Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia

G. Marcucci, I. Aldoss, P. Curtin, 2021, Cancer.

Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia

G. Marcucci, I. Aldoss, S. Forman, 2020, American journal of hematology.

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide

J. Wong, G. Marcucci, I. Aldoss, 2022, Blood advances.

Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification

E. Holler, Z. DeFilipp, Jung-Yi Lin, 2022, Blood advances.

Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation

Jeffery Y C Wong, G. Marcucci, I. Aldoss, 2021, Leukemia & lymphoma.

Long term outcomes of patients with Acute Myeloid Leukemia treated with myeloablative FTBI based conditioning with Tacrolimus and sirolimus based GVHD prophylaxis regimen: 6 year follow up from Single Center.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

G. Marcucci, I. Aldoss, S. Forman, 2019, American journal of hematology.

T. Slavin, G. Marcucci, I. Aldoss, 2018, Haematologica.

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT

J. Esteve, F. Baron, M. Labopin, 2019, Haematologica.

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

G. Marcucci, I. Aldoss, P. Curtin, 2022, Blood advances.

The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.

P. Vyas, C. Takimoto, S. Kambhampati, 2019, Journal of Clinical Oncology.

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results.

P. Vyas, R. Larson, S. Kambhampati, 2022, Journal of Clinical Oncology.

Red blood cell and platelet transfusion support in the first 30 and 100 days after allogeneic hematopoietic cell transplant

C. Karanes, R. Nakamura, Shan Yuan, 2020, Transfusion.

Allogeneic haematopoietic cell transplantation for extranodal natural killer/T‐cell lymphoma, nasal type: a CIBMTR analysis

Sonali M. Smith, M. Perales, E. Jacobsen, 2018, British journal of haematology.

Dasatinib-Induced Colitis after Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

I. Aldoss, S. Forman, V. Pullarkat, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation

G. Marcucci, I. Aldoss, S. Forman, 2021, Bone Marrow Transplantation.

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.

R. Soiffer, M. Grunwald, N. Ghosh, 2021, Blood.

Treatment of allosensitized patients receiving allogeneic transplantation

A. Nademanee, S. Forman, R. Champlin, 2021, Blood advances.

RBC and platelet transfusion support in the first 30 and 100 days after haploidentical hematopoietic stem cell transplantation

R. Nakamura, Shan Yuan, Dongyun Yang, 2019, Transfusion.

Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients

G. Marcucci, S. Forman, R. Nakamura, 2021, Transplantation and Cellular Therapy.

Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia

F. Pichiorri, L. Ghoda, G. Marcucci, 2019, Leukemia.

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide.

Shannon R. McCurdy, M. Perales, R. Soiffer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia.

An Liu, T. Schultheiss, J. Wong, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide.

Shannon R. McCurdy, M. Norkin, M. Perales, 2018, Blood advances.

Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib

G. Marcucci, R. Nakamura, H. Ali, 2022, Bone Marrow Transplantation.

New strategies for mismatched unrelated donor (MMUD) hematopoietic cell transplant (HCT).

Shukaib Arslan, M. A. Al Malki, 2022, Hematology. American Society of Hematology. Education Program.

Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia.

A. Nademanee, R. Champlin, S. Solomon, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch

A. Nademanee, S. Forman, D. Snyder, 2020, Transplantation.

HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis.

R. Soiffer, M. Grunwald, N. Ghosh, 2021, Blood.

Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation.

A. Ganser, M. Labopin, A. Nagler, 2020, Blood advances.

Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones.

I. Aldoss, S. Forman, D. Snyder, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia

An Liu, J. Wong, G. Marcucci, 2022, Frontiers in Oncology.

Risk of subsequent malignant neoplasms following hematopoietic stem cell transplantation with total body irradiation or total marrow irradiation: insights from early follow-up.

J. Wong, S. Dandapani, S. Armenian, 2022, Transplantation and cellular therapy.

Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients

A. Nademanee, I. Aldoss, S. Forman, 2020, Annals of Internal Medicine.

Total marrow irradiation reduces organ damage and enhances tissue repair with the potential to increase the targeted dose of bone marrow in both young and old mice

G. Storme, S. Hui, S. Dandapani, 2022, Frontiers in Oncology.

Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study

P. Hari, J. Perkins, J. Lipton, 2017, British journal of haematology.

Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia

J. Zaia, J. Ito, J. Kriengkauykiat, 2019, Transplant infectious disease : an official journal of the Transplantation Society.

Bortezomib for the prevention and treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Yuxin Feng, U. Duffner, A. Abdel-Mageed, 2016, Experimental hematology.

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

M. Perales, Richard J. Jones, Y. Efebera, 2022, Blood.

Tacrolimus initial steady state level in post-transplant cyclophosphamide based GvHD prophylaxis regimens

G. Marcucci, I. Aldoss, S. Forman, 2021, Bone Marrow Transplantation.

Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.

M. Pasquini, J. Wingard, K. Ballen, 2019, Blood advances.

Effective treatment of low risk acute GVHD with itacitinib monotherapy.

Z. DeFilipp, A. Alousi, M. Qayed, 2022, Blood.

Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

A. Nademanee, G. Marcucci, S. Forman, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia.

I. Aldoss, S. Forman, D. Snyder, 2016, Clinical Lymphoma, Myeloma & Leukemia.

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study

I. Flinn, P. Vyas, S. Kambhampati, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Implications and Management of Central Nervous System Involvement before Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia.

I. Aldoss, S. Forman, V. Pullarkat, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study

G. Marcucci, I. Aldoss, S. Forman, 2023, Frontiers in Immunology.

The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis.

F. Gao, P. Westervelt, J. Dipersio, 2022, Blood.

High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia‐like fusions

G. Marcucci, I. Aldoss, P. Curtin, 2023, American journal of hematology.

S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS

S. Kambhampati, N. Daver, G. Ramsingh, 2022, Clinical lymphoma, myeloma & leukemia.

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Ashutosh Kumar Singh, L. Adès, H. Carraway, 2022, Blood.

The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study

G. Marcucci, S. Forman, R. Nakamura, 2023, Stem Cell Research & Therapy.

Philadelphia chromosome as a recurrent event among therapy‐related acute leukemia

G. Marcucci, I. Aldoss, S. Forman, 2017, American journal of hematology.

Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration.

Shannon R. McCurdy, R. Varadhan, L. Gondek, 2023, Haematologica.

Tocilizumab for Cytokine Release Syndrome Management after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.

G. Marcucci, I. Aldoss, P. Curtin, 2023, Transplantation and cellular therapy.

Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study.

S. Forman, J. Chavez, B. Shah, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.

R. Varadhan, C. Huff, M. Perales, 2023, The New England journal of medicine.

Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias

G. Marcucci, I. Aldoss, A. Salhotra, 2021, Blood.

Association of pre-transplant vancomycin resistant enterococcus colonization status on long-term outcomes of allogeneic-hematopoietic cell transplantation

S. Forman, A. Artz, R. Spielberger, 2022, Bone Marrow Transplantation.

MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results.

S. Kambhampati, I. Flinn, D. Pollyea, 2022, Clinical lymphoma, myeloma & leukemia.

Specificity of HLA monoclonal antibodies and their use to determine HLA expression on lymphocytes and peripheral blood stem cells.

K. Gendzekhadze, M. A. Al Malki, M. Taniguchi, 2023, HLA.

A Phase 1 Dose-Escalation Study of the Oral CDK Inhibitor Voruciclib in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia (AML): Preliminary Results of the Completed Dose Escalation Stage in AML

M. Konopleva, O. Frankfurt, M. Davids, 2021, Blood.